LONDON, March 11, 2014 /PRNewswire/ --
On Monday, March 10, 2014, the
NASDAQ Composite ended at 4,334.45, down 0.04%, the Dow Jones
Industrial Average fell 0.21% to 16,418.68, and the S&P 500
closed at 1,877.17, down 0.05%. The losses were broad based as six
out of ten sectors ended the session in negative. The S&P 500
Health Care Sector Index finished the day at 689.78, up 0.39%, and
has gained 4.92% in the last one month. Investor-Edge.com has
initiated coverage on the following equities: Rexahn
Pharmaceuticals Inc. (NYSE MKT: RNN), Amgen Inc. (NASDAQ: AMGN),
Galena Biopharma Inc. (NASDAQ: GALE), and MannKind Corporation
(NASDAQ: MNKD). Free research on these four companies can be
accessed at:
http://investor-edge.com/register
Shares in Rexahn Pharmaceuticals Inc. closed at $1.25 on Monday, which is 5.68% lower than the
previous day's closing price of $1.32. A total of 8.48 million shares were
traded, which is below the three months average volumes of 11.22
million. The company's shares oscillated between $1.22 and $1.32 during the trading session.
Rexahn Pharmaceuticals Inc.'s shares have rallied 11.16% in the
last one month, 215.19% in the previous three months and 144.12% on
YTD basis. The stock is trading above its 50-day and 200-day moving
averages. The company's 50-day moving average of $1.03 is above the 200-day moving average of
$0.60. Furthermore, the stock is
trading at the Relative Strength Index (RSI) of 58.19. Sign up and
read the free notes on RNN at:
http://www.Investor-Edge.com/03112014/RNN/report.pdf
Amgen Inc.'s stock witnessed trading of 3.79 million shares, as
compared with a three month average volume of 3.29 million shares.
The stock ended the day at $125.40,
up 2.57% and at an intraday trading range of $122.25 and $126.10
during the session. The stock traded at a PE ratio of 17.15. Amgen
Inc.'s shares have gained 4.24% in the last one month, 9.90% in the
previous three months and 9.92% on YTD basis. The stock is trading
above its 50-day and 200-day moving averages. Amgen Inc.'s 50-day
moving average of $119.82 is above
the 200-day moving average of $111.66. Additionally, shares of the company are
trading at the Relative Strength Index (RSI) of 49.83. The
complimentary notes on AMGN can be downloaded as in PDF format
at:
http://www.Investor-Edge.com/03112014/AMGN/report.pdf
On Monday, shares in Galena Biopharma Inc. surged 4.76%
finishing the session at $3.52. The
stock recorded trading volume of 5.13 million shares as compared to
a three months average volume of 8.99 million shares. The company's
shares fluctuated between $3.38 and
$3.65 during the session and traded at a PE ratio of 29.33.
Galena Biopharma Inc.'s shares have gone down by 9.28% in the
previous three trading sessions, 34.69% in the last one month, and
29.03% on YTD basis. The stock is trading above its 200-day moving
average. Galena Biopharma Inc.'s 50-day moving average of
$4.92 is above the 200-day moving
average of $3.07. Moreover, shares of
the company are trading at the Relative Strength Index (RSI) of
35.08. Register for free on Investor-Edge and access the latest
research on GALE at:
http://www.Investor-Edge.com/03112014/GALE/report.pdf
Shares in MannKind Corp. recoded a trading volume of 5.65
million shares, as compared with a three month average volume of
7.16 million shares. The stock ended Monday's session flat at the
previous day's closing price of $5.71
after vacillating between $5.60 and
$5.85. Shares in MannKind Corp. have
advanced 0.35% in the last one month, 15.59% in the previous three
months and 9.81% on YTD basis. The company's shares are trading
above its 50-day moving average. MannKind Corp.'s 200-day moving
average of $5.98 is above the 50-day
moving average of $5.70. Furthermore,
the stock is trading at the Relative Strength Index (RSI) of 45.73.
The complete research on MNKD is available for free at:
http://www.Investor-Edge.com/03112014/MNKD/report.pdf
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and
reliable way to leverage our economy of scale. Most investors do
not have time to track all publicly traded companies, much less
perform an in-depth review and analysis of the complexities
contained in each situation. That's where Investor-Edge comes in.
We provide a single unified platform for investors' to hear about
what matters. Situation alerts, moving events, and upcoming
opportunities.
=============
EDITOR NOTES:
=============
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] Investor-edge.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] Investor-edge.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] Investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge